Biotechs fear OGTR cost recovery could quash R&D
05 July, 2002 by Melissa TrudingerPlant biotechnologists in Australia are concerned that implementation of a full cost recovery scheme for the Office of the Gene Technology Regulator will make the cost of developing new GM crop varieties too expensive for small biotechnology companies and public research institutions to consider.
Chemeq's drug approved for sale in South Africa
04 July, 2002 by Melissa TrudingerChemeq has announced that it has received its first regulatory approval for sale of its veterinary drug CHEMEQ polymeric antimicrobial in South Africa.
Views on GM polarised: WA survey
04 July, 2002 by Pete YoungA Western Australian government survey of public and industry views has revealed strongly-polarised views about the costs and benefits of introducing genetically modified crops, says Agriculture Minister Kim Chance.
Federal funding recieved for foot and mouth monitoring
03 July, 2002 by Melissa TrudingerCSIRO's Australian Animal Health Laboratory has received $1 million from the Federal government to improve systems for prevention of foot and mouth disease outbreaks in Australia.
CSIRO and GRDC team up to study grain crop problems
03 July, 2002 by Melissa TrudingerCSIRO Entomology and the Grains Research and Development Corporation have signed a $20 million agreement for a research alliance focusing on the pests and diseases affecting Australia's grain industries.
Virax files prostate cancer therapy patent
02 July, 2002 by Tanya HollisImmune-based drug developer Virax Holdings has announced it had filed a patent relating to a potential new prostate cancer therapy.
GTG claims progress made in AIDS research
02 July, 2002 by Melissa TrudingerMelbourne company Genetic Technologies has reported that it is making good progress with its AIDS research project.
Peptech seeks approval for dog contraceptive
02 July, 2002 by Tanya HollisPeptech's animal health division has applied to register its medication to control fertility and reproductive behaviour in dogs.
Peplin overcomes scale-up hurdles and exports cancer drug
02 July, 2002 by Pete YoungPeplin Biotech has shipped the first significant quantity of its lead anti-cancer drug PEP 005 after a year-long effort which it says has "cracked the back" of any manufacturing problems.
Acrux raises $9.8m to speed drug delivery program
02 July, 2002 by Tanya HollisNovel drug delivery company Acrux has raised $9.8 million through the sale of 10 per cent of its stock to Queensland Investment Corporation.
Eiffel signs new drug delivery agreement
01 July, 2002 by Tanya HollisEiffel Technologies has signed a new agreement with specialist UK drug company Profile Therapeutics to investigate delivery methods for an undisclosed pharmaceutical compound.
Canola pollen travels... but doesn't do much when it arrives
01 July, 2002 by Melissa TrudingerPollen from a herbicide-tolerant canola crop spreads to neighbouring fields, according to Australian study published in the June 28th issue of Science, but only a very low percentage of plants are fertilised there.
Varian to open HPLC production facility in Melbourne
28 June, 2002 by Tanya HollisVictoria has won a key investment in a $US200 million coup that sees a Silicon Valley production facility shift its base to Melbourne's east.
Xcell appoints regulatory team for US, Europe push
27 June, 2002 by Tanya HollisPerth-based devices group Xcell Diagnostics has gathered up a specialised regulatory affairs team to drive United States and European registration of its Funhaler product.
GM sensitivities force caution on biotech R&D
27 June, 2002 by Pete YoungConsumer sensitivities over genetically modified foods are forcing biotech researchers in Australia's sugar industry to walk a tightrope.
